Last reviewed · How we verify
DFPP + Peg-IFN + RBV
DFPP removes circulating immune complexes and pathogenic antibodies, while pegylated interferon-alpha and ribavirin work synergistically to inhibit hepatitis C virus replication and enhance immune response.
DFPP removes circulating immune complexes and pathogenic antibodies, while pegylated interferon-alpha and ribavirin work synergistically to inhibit hepatitis C virus replication and enhance immune response. Used for Chronic hepatitis C virus infection, particularly in treatment-experienced or difficult-to-treat patients.
At a glance
| Generic name | DFPP + Peg-IFN + RBV |
|---|---|
| Also known as | DFPP: Plasmaflo + Cascadeflo EC-50W (Asahi), Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche), RBV: Copegus (Hoffman La-Roche) |
| Sponsor | National Taiwan University Hospital |
| Drug class | Combination antiviral therapy with immunomodulation |
| Target | Hepatitis C virus NS5B polymerase (RBV); interferon-alpha receptor (Peg-IFN); circulating immune complexes (DFPP) |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Double filtration plasmapheresis (DFPP) is an extracorporeal blood purification technique that selectively removes large molecular weight substances including immune complexes and immunoglobulins. When combined with pegylated interferon-alpha (Peg-IFN), which activates innate immunity and has direct antiviral effects, and ribavirin (RBV), a nucleoside analog that inhibits viral RNA synthesis, this triple modality targets hepatitis C virus through multiple mechanisms: reducing viral load, clearing immune-mediated damage, and enhancing interferon-based antiviral immunity.
Approved indications
- Chronic hepatitis C virus infection, particularly in treatment-experienced or difficult-to-treat patients
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Flu-like symptoms
- Vascular access complications (from DFPP)
- Depression/mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFPP + Peg-IFN + RBV CI brief — competitive landscape report
- DFPP + Peg-IFN + RBV updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI